Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 4,400 shares of Atara Biotherapeutics stock in a transaction on Thursday, October 12th. The stock was sold at an average price of $15.02, for a total value of $66,088.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Atara Biotherapeutics, Inc. (ATRA) traded down 2.31% on Thursday, reaching $14.80. The company’s stock had a trading volume of 251,935 shares. Atara Biotherapeutics, Inc. has a 52-week low of $11.80 and a 52-week high of $23.00. The firm’s 50-day moving average price is $15.55 and its 200-day moving average price is $15.46. The stock’s market cap is $452.27 million.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.89) by ($0.05). On average, equities analysts expect that Atara Biotherapeutics, Inc. will post ($3.90) earnings per share for the current year.

WARNING: This report was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.thecerbatgem.com/2017/10/12/insider-selling-atara-biotherapeutics-inc-atra-ceo-sells-4400-shares-of-stock.html.

Hedge funds have recently bought and sold shares of the company. Voya Investment Management LLC raised its position in shares of Atara Biotherapeutics by 16.2% in the 2nd quarter. Voya Investment Management LLC now owns 11,813 shares of the biotechnology company’s stock worth $165,000 after acquiring an additional 1,651 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Atara Biotherapeutics in the 2nd quarter worth about $252,000. The Manufacturers Life Insurance Company raised its position in shares of Atara Biotherapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,377 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 1,369 shares in the last quarter. American International Group Inc. raised its position in shares of Atara Biotherapeutics by 7.1% in the 1st quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 948 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its position in shares of Atara Biotherapeutics by 2.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 21,718 shares of the biotechnology company’s stock worth $304,000 after acquiring an additional 610 shares in the last quarter. 82.95% of the stock is owned by hedge funds and other institutional investors.

A number of brokerages recently commented on ATRA. Zacks Investment Research raised Atara Biotherapeutics from a “sell” rating to a “hold” rating and set a $15.00 price objective for the company in a research note on Tuesday, August 22nd. ValuEngine cut Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a research note on Monday, June 26th. Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research note on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and set a $20.00 price objective on shares of Atara Biotherapeutics in a research note on Friday, October 6th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Atara Biotherapeutics presently has an average rating of “Hold” and an average price target of $24.40.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Stock Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.